Sunday, August 19, 2012

Alemtuzumab in MS

In patients with relapsing-remitting MS, alemtuzumab was found to be superior to interferon beta 1-a . Patients were randomized to 12 mg of alemtuzumab for 5 days at month 0 and 3 days at month 12 by infusion or 44 mcg qod with interferon beta 1-a.
Neurology 2012;78:(14):1069-1078
Lancet Neurology 2011;10(4):338-348

No comments:

Post a Comment